1. Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation 
Carmen Di Grazia, Sarah Pozzi, Simona Geroldi, Raffaella Grasso, Maurizio Miglino, Nicoletta Colombo, Elisabetta Tedone, Silvia Luchetti, Teresa Lamparelli, Francesca Gualandi, Adalberto Ibatici, Stefania Bregante, Maria Teresa Van Lint, Anna Maria Raiola, Alida Dominietto, Riccardo Varaldo, Federica Galaverna, Anna Ghiso, Simona Sica, Andrea Bacigalupo 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 7, Pages (July 2016)
DOI: /j.bbmt
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
WT1 copies/104 Abl in a 58-year-old patients with relapsed/refractory AML. CyA disc indicates cyclosporin A discontinuation; DLI, donor lymphocyte infusions.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Cumulative incidence of relapse in MRD-positive patients treated with immunotherapy (IT) at a cut-off level of 180 copies/104 Abl (WT1-180) (n = 17) or 100 copies/104 Abl (WT1-100) (n = 23).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Disease-free survival of MRD-positive patients treated with IT at a cut-off level of WT1 of 180 copies/104 Abl (WT1-180) (n = 17) or 100 copies/104 Abl (WT1-100) (n = 23).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Overall cumulative incidence of TRM and of relapse in 122 patients, monitored for WT1 expression and eligible for IT at a cut-off of 180 copies (WT1-180) and in 85 patients monitored and eligible for IT at a cut-off level of 100 copies (WT1-100).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Overall disease-free survival of the 2 groups of AML patients, as described in Figure 4 (WT1-180 and WT1-100).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2016 American Society for Blood and Marrow Transplantation Terms and Conditions